
Sign up to save your podcasts
Or


Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll.
Get $50 off your first job post at www.LinkedIn.com/Fool.
By The Motley Fool4.7
16041,604 ratings
Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll.
Get $50 off your first job post at www.LinkedIn.com/Fool.

3,237 Listeners

1,497 Listeners

806 Listeners

941 Listeners

533 Listeners

1,182 Listeners

2,186 Listeners

825 Listeners

1,428 Listeners

1,051 Listeners

9,714 Listeners

195 Listeners

829 Listeners

83 Listeners

49 Listeners

1,024 Listeners

50 Listeners